Metformin and Sitagliptin in Women With Previous Gestational Diabetes

Pre-diabetes Clinical Trial

Official title:

Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Women With Previous Gestational Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01336322
• Other study ID #: SITA-previousGDM
• Status: Completed
• Phase: Phase 2
• Start date: May 2011
• Est. completion date: December 2018

Study information

• Verified date: March 2019
• Source: University of Pisa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the present research is to compare the effects of treatment with metformin and sitagliptin, alone or in association, in women with previous gestational diabetes to evaluate the impact of the two drugs on beta-cell function. The study results may contribute to give a rational approach for future investigations.

Description:

A randomized, double blinded study, on 45 women with previous gestational diabetes and impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) to assess the effects of a 4-month treatment with metformin and/or a dipeptidyl peptidase-4 inhibitor (sitagliptin) on beta-cell function and insulin resistance.

At baseline, all women will have a standardized medical history, physical, and laboratory examination. Plasma glucose, insulin, pro-insulin, C-peptide, glucagon, adipokines, pro-inflammatory molecules, and lipid profile will be determined in fasting condition. A 75g OGTT will be performed after an overnight fasting and sample will be drawn at 15, 30, 60, 90 and 120 minutes for plasma glucose, C-peptide, glucagon and GLP-1 determinations. Women with IFG or IGT will be recruited and undergo to a hyperglycemic clamp with arginin bolus at the end of the test. Then the women will be randomized in 3 treatment groups: metformin (850 mg bid), sitagliptin (100 mg qd)or metformin (850 mg bid) + sitagliptin (100 mg qd). After 4-month treatment, the baseline evaluation will be repeated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Female subjects aged =18 and =45 years

• Caucasian race

• History of previous gestational diabetes (in the screening) during pregnancy.

• Female of childbearing potential must use effective contraceptive measures for at last 1 month prior to entry into the study and should continue to use the some contraceptive method during the overall study period

• Written informed consent obtained

Exclusion Criteria:

• Patients diagnosed with type 1 insulin dependent diabetes

• Diagnosis of diabetes in the 75g OGTT performed at entry

• BMI =18 or =50 Kg/m2

• Chronic impaired renal function

• Impaired liver function as shown by transaminase levels = twice above the upper normal range

• History of hypersensitivity to metformin

• Pregnant or breast-feeding women, or women planning to become pregnant during the study

• Failure to use adequate contraception (Women of current reproductive only)

• Mental condition rending the subject unable to understand the nature, scope and possible consequences of the study

• Any clinically significant major organ system disease

• Patients with underlying concomitant medication requiring a long-term use of drugs potentially acting on glucose metabolism (e.g. corticosteroids, diuretics, beta-adrenergic drugs or others)

• Treatment or likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol

• History of drug or alcohol abuse within the last 2 years or current addiction to substances of abuse

• Any disease or condition that in the opinion of the investigator may interfere with the completion of the study

• Subjects unlikely to comply with the protocol

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes, Gestational
• Glucose Intolerance
• Insulin Resistance
• Pre-diabetes
• Prediabetic State

Intervention

Drug:
• Metformin
Metformin 850 mg bid
• Sitagliptin
Sitagliptin 100 mg qd
• Sitagliptin + Metformin
sitagliptin 100mg + metformin 850mg

Locations

Country	Name	City	State
Italy	Department of Endocrinology and Metabolism, University of Pisa	Pisa

Sponsors (2)

Lead Sponsor	Collaborator
University of Pisa	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Beta-cell function	Sitagliptin and/or metformin effects on beta-cell function (ISR = Insulin Secretion Rate) evaluated by mathematical model by Mari A. (Am J Physiology 2002)	4 months
Secondary	Insulin resistance	Sitagliptin and/or metformin effects on insulin resistance, evaluated by clamp, HOMA-index and ISI-Method..	4 months
Secondary	Glucose control	Sitagliptin and/or metformin effects on glucose control evaluated by OGTT and HbA1c levels.	4 months